Evidence map›Paper›PMID 41120963›Full record

ArticleBMC infectious diseases2025

Determinants of hepatitis C virus treatment completion among Los Angeles County residents.

Cassidy Hernandez-Tamayo, Chrysovalantis Stafylis, Lokesh Bhardwaj, Riya K Shah, Tatiana Becerra, Dara Bruce, Roopkamal Saini, Natalie Saremi, Immanuel Thomas, Krzel Manansala-Tan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Cassidy Hernandez-TamayoKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA. cassidyj@usc.edu.
Chrysovalantis StafylisKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Lokesh BhardwajKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Riya K ShahKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Tatiana BecerraKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Dara BruceKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Roopkamal SainiKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Natalie SaremiKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Immanuel ThomasKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Krzel Manansala-TanKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Arjun P VijKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Alison LiKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Nathan SudeepKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Jacob GizambaKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Bijan HosseiniKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Sabrina NavarroKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Sofia Ufret-RiveraKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Albert J FariasKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA.
Jeffrey D KlausnerKeck School of Medicine Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA. jdklausner@med.usc.edu.

Funding

Southern California Clinical and Translational Science Institute UL1TR001855
6 · The paper itself

Abstract

backgroundHepatitis C viral infection is curable, yet only about one-third of identified cases have been cleared nationally. We evaluated determinants of treatment completion in a sample of newly reported hepatitis C cases among Los Angeles County residents.

methodsUsing information from the Los Angeles County Hepatitis C Case Registry, we contacted reported hepatitis C ribonucleic acid (RNA) positive cases diagnosed from January 2021 through April 2022. We used Pearson's Chi-Square Tests and multivariable logistic regression to identify demographic and clinical characteristics associated with self-reported hepatitis C virus treatment completion.

resultsAmong 2,992 reported RNA-positive cases, 619 (21%) were successfully contacted. Among those, most respondents were untreated (72%), male (65%), and tested by primary care providers (50%). Individuals 30-44 years old had 2.9 (95% CI: 1.1, 7.4) times the odds of having completed treatment during initial contact compared to 18-29 year-olds, adjusted for ordering provider type, race/ethnicity, health insurance type, and symptom status. Respondents tested by specialists had 1.8 (95% CI: 1.2, 2.8) times the odds of completing treatment compared to those tested by primary care providers. Respondents who reported symptoms in the past six months had 0.2 (95% CI: 0.1, 0.4) times the odds of completing treatment compared to respondents with no symptoms. Characteristics of respondents were the same as those diagnosed with hepatitis C in Los Angeles County.

conclusionsWe verified low hepatitis C treatment completion at the population-level. Those 18-29 years old and diagnosed in primary care were least likely to complete treatment.

Indexed as

Antiviral AgentsHepatitis CAdolescentAdultAgedFemaleHepacivirusHumansLos AngelesMaleMiddle AgedYoung AdultAntiviral AgentsDirect acting antiviral therapyHepatitis C treatmentHepatitis C virus

Identifiers

PMID41120963
PMCPMC12538750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.